Last edition
News about
KORU Medical Gains EU MDR Approval For Freedom60 Infusion Pump
KORU Medical Systems has announced that its Freedom60 Infusion Pump, including the adapter designed for use with 50 mL prefilled syringes, has received certification under the European Union Medical Devices Regulation (EU MDR 2017/745). The certification allows the company to commercialise the device across the European Union.
Middle East Conflict Disrupts Pharma Air Routes, Threatens Supply Of Cancer Drugs
The ongoing conflict in the Middle East is disrupting critical air cargo routes used to transport pharmaceutical products, raising concerns about the timely supply of cancer medicines and other temperature-sensitive treatments to the Gulf region.
Zuellig Pharma has acquired rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea, expanding its ownership of the men’s health drug across 11 Asian markets.
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Meiji Seika Pharma Initiates Phase I Trial of ME3241 PD-1 Agonist Antibody for Autoimmune Diseases
Meiji Seika Pharma Co., Ltd. has launched a Phase I clinical trial of ME3241, a novel anti-PD-1 agonist antibody developed with Foundation for Biomedical Research and Innovation at Kobe for autoimmune disease treatment.
Aplagon Doses First Patient in Phase IIa Trial of APAC for Chronic Limb-Threatening Ischemia
Aplagon has dosed the first patient in its Phase IIa HEALING trial evaluating APAC therapy for Chronic Limb?Threatening Ischemia caused by Peripheral Arterial Occlusive Disease in Finland.
Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
The collaboration between Aptar Pharma and COVIRIX Medical Partner will focus on a feasibility study to adapt Aptar Pharma’s proprietary Dry Powder Inhalation (DPI) platform for the delivery of COVIRIX Medical’s anti-viral compound.
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
US FDA Approves GSK's AREXVY for At-Risk Adults Aged 18 to 49 Years
The US FDA has approved GSK’s RSV vaccine, AREXVY, for adults aged 18–49 who are at increased risk of severe RSV infection, expanding protection to an estimated 21 million at-risk individuals in this age group.
Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide
Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy